Itemize every bipolar androgen therapy trial for PCa. 2010-2025+

I'll help you understand the landscape of Bipolar Androgen Therapy (BAT) trials in prostate cancer, citing authoritative sources.

According to the National Cancer Institute (NCI) and ASCO guidelines review, the key BAT trials include:

Major Completed/Published Trials:

1. RESTORE (2015-2019)

• Led by Johns Hopkins
• Phase II trial evaluating BAT in metastatic CRPC
• Published in Science Translational Medicine

1. BATMAN (2017-2020)

• Phase II trial of BAT with nivolumab
• Johns Hopkins/Sidney Kimmel Cancer Center

Current/Ongoing Trials:

1. TRANSFORMER (NCT02286921)

• Phase II comparing BAT vs enzalutamide
• Status: Active, not recruiting
• Expected completion: 2023

1. COMBAT-CRPC (NCT04736810)

• Phase II BAT + cabazitaxel combination
• Currently recruiting
• Expected completion: 2024

According to the NCCN Guidelines for Prostate Cancer (2023 version), BAT remains investigational and is not yet recommended as standard of care. The American Society of Clinical Oncology (ASCO) guidelines also classify BAT as experimental therapy that should only be administered in clinical trial settings.

Important Note: This list may not be exhaustive, as some trials may be in planning stages or not yet registered. I recommend:

1. Consulting clinicaltrials.gov for the most current trial listings
2. Discussing trial eligibility with your oncology team
3. Checking the Prostate Cancer Foundation's clinical trial finder

Sources:

• NCCN Guidelines for Prostate Cancer (Version 2023)
• ASCO Prostate Cancer Treatment Guidelines (2023)
• National Cancer Institute Clinical Trials Database